Molecular Mechanisms of Qingfei Paidu Decoction in the Prevention and Treatment of Acute Lung Injury in Mice Based on miRNA Sequencing

doi:10.12300/j.issn.1674-5817.2025.203

Abstract

Abstract:

Objective To investigate the preventive and therapeutic effects of Qingfei Paidu decoction (QFPDD) on acute lung injury (ALI) in mice and its underlying molecular mechanisms based on miRNA sequencing technology. Methods Twenty-four 4-week-old male KM mice were randomly divided into a control group, a model group, and a QFPDD group (n = 8 per group). After one week of acclimatization, mice in the control and model groups were intragastrically administered ultrapure water (0.2 mL per dose), whereas mice in the QFPDD group were intragastrically administered QFPDD (1.6 g crude drug/mL, 0.2 mL per dose), twice daily for 8 consecutive days. On days 2–8, mice in the model and QFPDD groups were exposed to aerosolized lipopolysaccharide (LPS) solution (2.5 g/L, 4 mL per exposure) for 7 consecutive days. On day 9, blood was collected via the retro-orbital venous plexus under deep anesthesia, and lung tissues were harvested. Body weight and lung weight were measured, and the lung coefficient was calculated. Serum levels of inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 were detected by ELISA. Lung histopathological changes were observed by HE staining of paraffin-embedded sections. miRNA expression profiles in lung tissues were analyzed using the Illumina HiSeq 2500 sequencing platform. Target genes of differentially expressed miRNAs were predicted using bioinformatics databases, and functional enrichment analysis of these target genes was performed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Differentially expressed miRNAs were validated by reverse transcription quantitative real-time PCR (RT-qPCR). Results Compared with the control group, the model group showed a consistent body weight growth trend but a significantly increased lung coefficient (P < 0.01). ELISA results showed that serum levels of TNF-α and IL-6 were significantly elevated in the model group compared with the control group (P < 0.01), whereas QFPDD treatment significantly reduced serum TNF-α and IL-6 levels compared with the model group (P < 0.05). HE staining showed that, compared with the control group, the model group exhibited widened alveolar septa, massive inflammatory cell infiltration, partial alveolar expansion, and mild capillary dilation with congestion. In contrast, the QFPDD group showed only slightly widened alveolar septa and mild inflammatory cell infiltration compared with the model group. Intersection analysis of miRNA sequencing data identified 13 differentially expressed miRNAs common to both the model vs. control and QFPDD vs. model comparisons. Among them, 6 miRNAs (mmu-miR-203-3p, mmu-miR-181b-5p_R-1, hsa-miR-4286_R+1, mmu-miR-1843b-5p_L+1R-1_2, mmu-miR-22-3p, and mmu-miR-1964-3p) were significantly up-regulated in the model group (P < 0.05) and significantly down-regulated after QFPDD treatment (P < 0.05), showing a therapeutic reversal trend. GO analysis revealed that the target genes of the differentially expressed miRNAs were mainly enriched in biological processes such as RNA polymerase Ⅱ transcriptional regulation. KEGG analysis indicated that target genes were mainly enriched in signaling pathways including the mitogen-activated protein kinase (MAPK) pathway. RT-qPCR validation result for mmu-miR-203-3p was consistent with the sequencing analysis results. Conclusion QFPDD may exert preventive and therapeutic effects against ALI by regulating the expression of mmu-miR-203-3p and other miRNAs, thereby modulating inflammatory responses and the MAPK signaling pathway and participating in the pathological process of lung injury.

Key words: Qingfei Paidu decoction, Acute lung injury, miR-203-3p, Inflammation, MAPK signaling pathway, KM mice

CLC Number:

Q95-33
R-332

LI Longxue,LI Longxue,WAN Chongfan,et al. Molecular Mechanisms of Qingfei Paidu Decoction in the Prevention and Treatment of Acute Lung Injury in Mice Based on miRNA Sequencing[J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 311-320. DOI: 10.12300/j.issn.1674-5817.2025.203.

Figures/Tables 12

References 28

[1]	LIU H Q, DONG J L, XU C L, et al. Acute lung injury: pathogenesis and treatment[J]. J Transl Med, 2025, 23(1): 926. DOI: 10.1186/s12967-025-06994-2 .
	LIU H Q, DONG J L, XU C L, et al. Acute lung injury: pathogenesis and treatment[J]. J Transl Med, 2025, 23(1): 926. DOI: 10.1186/s12967-025-06994-2 .
[2]	VERMA N, HOCHHEGGER B, MUKHOPADHYAY S, et al. Acute lung injury[J]. J Thorac Imag, 2025, 40(3): e0820. DOI: 10.1097/rti.0000000000000820 .
	VERMA N, HOCHHEGGER B, MUKHOPADHYAY S, et al. Acute lung injury[J]. J Thorac Imag, 2025, 40(3): e0820. DOI: 10.1097/rti.0000000000000820 .
[3]	国家卫生健康委, 国家中医药局. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 传染病信息, 2023, 36(1): 18-25. DOI: 10.3760/j.issn.1673-4777.2023.02.001 .
	国家卫生健康委, 国家中医药局. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 传染病信息, 2023, 36(1): 18-25. DOI: 10.3760/j.issn.1673-4777.2023.02.001 .
	National Health Commission of the PRC, National Administration of Traditional Chinese Medicine. Guideline on diagnosis and treatment of novel coronavirus pneumonia(interim 10th edition)[J]. Infect Dis Inf, 2023, 36(1): 18-25. DOI: 10.3760/j.issn.1673-4777.2023.02.001 .
	National Health Commission of the PRC, National Administration of Traditional Chinese Medicine. Guideline on diagnosis and treatment of novel coronavirus pneumonia(interim 10th edition)[J]. Infect Dis Inf, 2023, 36(1): 18-25. DOI: 10.3760/j.issn.1673-4777.2023.02.001 .
[4]	LU J N, TANG Y, LI H T, et al. Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D[J]. Nat Prod Bioprospect, 2025, 15(1): 39. DOI: 10.1007/s13659-025-00523-w .
	LU J N, TANG Y, LI H T, et al. Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D[J]. Nat Prod Bioprospect, 2025, 15(1): 39. DOI: 10.1007/s13659-025-00523-w .
[5]	REN W, MA Y, WANG R Q, et al. Research advance on Qingfei Paidu decoction in prescription principle, mechanism analysis and clinical application[J]. Front Pharmacol, 2021, 11: 589714. DOI: 10.3389/fphar.2020.589714 .
	REN W, MA Y, WANG R Q, et al. Research advance on Qingfei Paidu decoction in prescription principle, mechanism analysis and clinical application[J]. Front Pharmacol, 2021, 11: 589714. DOI: 10.3389/fphar.2020.589714 .
[6]	YE X L, TIAN S S, TANG C C, et al. Cytokine storm in acute viral respiratory injury: role of Qing-Fei-Pai-Du decoction in inhibiting the infiltration of neutrophils and macrophages through TAK1/IKK/NF-κB pathway[J]. Am J Chin Med, 2023, 51(5): 1153-1188. DOI: 10.1142/s0192415x23500532 .
	YE X L, TIAN S S, TANG C C, et al. Cytokine storm in acute viral respiratory injury: role of Qing-Fei-Pai-Du decoction in inhibiting the infiltration of neutrophils and macrophages through TAK1/IKK/NF-κB pathway[J]. Am J Chin Med, 2023, 51(5): 1153-1188. DOI: 10.1142/s0192415x23500532 .
[7]	张平, 潘广涛. 清肺排毒汤改善新型冠状病毒肺炎危重型患者炎性细胞因子的临床研究[J]. 世界科学技术-中医药现代化, 2021, 23(2): 391-395. DOI: 10.11842/wst.20200416003 .
	张平, 潘广涛. 清肺排毒汤改善新型冠状病毒肺炎危重型患者炎性细胞因子的临床研究[J]. 世界科学技术-中医药现代化, 2021, 23(2): 391-395. DOI: 10.11842/wst.20200416003 .
	ZHANG P, PAN G T. Clinical study on the improvement of inflammatory cytokines in critically ill patients with COVID-19 treated by Qingfei Paidu decoction[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2021, 23(2): 391-395. DOI: 10.11842/wst.20200416003 .
	ZHANG P, PAN G T. Clinical study on the improvement of inflammatory cytokines in critically ill patients with COVID-19 treated by Qingfei Paidu decoction[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2021, 23(2): 391-395. DOI: 10.11842/wst.20200416003 .
[8]	ZHANG X, YU Y, NING Y, et al. Advances in microRNA promoting gene expression[J]. Hereditas, 2025, 47(7): 729-741. DOI: 10.16288/j.yczz.24-374 .
	ZHANG X, YU Y, NING Y, et al. Advances in microRNA promoting gene expression[J]. Hereditas, 2025, 47(7): 729-741. DOI: 10.16288/j.yczz.24-374 .
[9]	OLIVETO S, MANFRINI N, BIFFO S. The power of microRNA regulation: insights into immunity and metabolism[J]. FEBS Lett, 2025, 599(13): 1821-1851. DOI: 10.1002/1873-3468.70039 .
	OLIVETO S, MANFRINI N, BIFFO S. The power of microRNA regulation: insights into immunity and metabolism[J]. FEBS Lett, 2025, 599(13): 1821-1851. DOI: 10.1002/1873-3468.70039 .
[10]	MCGEARY S E, LIN K S, SHI C Y, et al. The biochemical basis of microRNA targeting efficacy[J]. Science, 2019, 366(6472): eaav1741. DOI: 10.1126/science.aav1741 .
	MCGEARY S E, LIN K S, SHI C Y, et al. The biochemical basis of microRNA targeting efficacy[J]. Science, 2019, 366(6472): eaav1741. DOI: 10.1126/science.aav1741 .
[11]	BARTEL D P. microRNA genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297. DOI: 10.1016/S0092-8674(04)00045-5 .
	BARTEL D P. microRNA genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297. DOI: 10.1016/S0092-8674(04)00045-5 .
[12]	ARTIMOVIČ P, ŠPAKOVÁ I, MACEJKOVÁ E, et al. The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways[J]. Genes Immun, 2024, 25(4): 277-296. DOI: 10.1038/s41435-024-00283-6 .
	ARTIMOVIČ P, ŠPAKOVÁ I, MACEJKOVÁ E, et al. The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways[J]. Genes Immun, 2024, 25(4): 277-296. DOI: 10.1038/s41435-024-00283-6 .
[13]	LI Y, PENG B, LI Y, et al. MiR-203a-3p/153-3p improves cognitive impairments induced by ischemia/reperfusion via blockade of SRC-mediated MAPK signaling pathway in ischemic stroke[J]. Chem Biol Interact, 2022, 358:109900. DOI: 10.1016/j.cbi.2022.109900 .
	LI Y, PENG B, LI Y, et al. MiR-203a-3p/153-3p improves cognitive impairments induced by ischemia/reperfusion via blockade of SRC-mediated MAPK signaling pathway in ischemic stroke[J]. Chem Biol Interact, 2022, 358:109900. DOI: 10.1016/j.cbi.2022.109900 .
[14]	DENG A X, ZHAO L, RUZE A, et al. Application of ultrasound in assessment of acute lung injury in mice[J]. PLoS One, 2025, 20(10): e0332912. DOI: 10.1371/journal.pone.0332912 .
	DENG A X, ZHAO L, RUZE A, et al. Application of ultrasound in assessment of acute lung injury in mice[J]. PLoS One, 2025, 20(10): e0332912. DOI: 10.1371/journal.pone.0332912 .
[15]	ZHANG M Q, SHANG L R, ZHOU F Y, et al. Dachengqi decoction dispensing granule ameliorates LPS-induced acute lung injury by inhibiting PANoptosis in vivo and in vitro [J]. J Ethnopharmacol, 2025, 336: 118699. DOI: 10.1016/j.jep.2024.118699 .
	ZHANG M Q, SHANG L R, ZHOU F Y, et al. Dachengqi decoction dispensing granule ameliorates LPS-induced acute lung injury by inhibiting PANoptosis in vivo and in vitro [J]. J Ethnopharmacol, 2025, 336: 118699. DOI: 10.1016/j.jep.2024.118699 .
[16]	LIU H Y, LIU Y Q, LIN X X, et al. Mitoxantrone attenuates lipopolysaccharide-induced acute lung injury via inhibition of NEDD8 activating enzyme[J]. Int Immunopharmacol, 2024, 143: 113605. DOI: 10.1016/j.intimp.2024.113605 .
	LIU H Y, LIU Y Q, LIN X X, et al. Mitoxantrone attenuates lipopolysaccharide-induced acute lung injury via inhibition of NEDD8 activating enzyme[J]. Int Immunopharmacol, 2024, 143: 113605. DOI: 10.1016/j.intimp.2024.113605 .
[17]	ZHANG H, WANG Y, WANG S H, et al. Tangeretin alleviates sepsis-induced acute lung injury by inhibiting ferroptosis of macrophage via Nrf2 signaling pathway[J]. Chin Med, 2025, 20(1): 11. DOI: 10.1186/s13020-025-01063-8 .
	ZHANG H, WANG Y, WANG S H, et al. Tangeretin alleviates sepsis-induced acute lung injury by inhibiting ferroptosis of macrophage via Nrf2 signaling pathway[J]. Chin Med, 2025, 20(1): 11. DOI: 10.1186/s13020-025-01063-8 .
[18]	LI D D, PAN L Y, CHEN M J, et al. TREM2 protects against LPS-induced murine acute lung injury through suppressing macrophage ferroptosis[J]. Int Immunopharmacol, 2025, 150: 114247. DOI: 10.1016/j.intimp.2025.114247 .
	LI D D, PAN L Y, CHEN M J, et al. TREM2 protects against LPS-induced murine acute lung injury through suppressing macrophage ferroptosis[J]. Int Immunopharmacol, 2025, 150: 114247. DOI: 10.1016/j.intimp.2025.114247 .
[19]	MA W T, ZHOU J X, QIAN Y, et al. Transcriptomics reveals the underlying mechanism of Prostaglandin E1 in improving severe pneumonia[J]. BMC Pulm Med, 2025, 25(1): 389. DOI: 10.1186/s12890-025-03847-y .
	MA W T, ZHOU J X, QIAN Y, et al. Transcriptomics reveals the underlying mechanism of Prostaglandin E1 in improving severe pneumonia[J]. BMC Pulm Med, 2025, 25(1): 389. DOI: 10.1186/s12890-025-03847-y .
[20]	FU J M, LIU Z L, FENG Z Y, et al. Platycodon grandiflorum exosome-like nanoparticles: the material basis of fresh Platycodon grandiflorum optimality and its mechanism in regulating acute lung injury[J]. J Nanobiotechnology, 2025, 23(1): 270. DOI: 10.1186/s12951-025-03331-z .
	FU J M, LIU Z L, FENG Z Y, et al. Platycodon grandiflorum exosome-like nanoparticles: the material basis of fresh Platycodon grandiflorum optimality and its mechanism in regulating acute lung injury[J]. J Nanobiotechnology, 2025, 23(1): 270. DOI: 10.1186/s12951-025-03331-z .
[21]	ZHOU M, MENG L, HE Q K, et al. Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways[J]. Front Pharmacol, 2024, 15: 1321095. DOI: 10.3389/fphar.2024. 1321095 .
	ZHOU M, MENG L, HE Q K, et al. Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways[J]. Front Pharmacol, 2024, 15: 1321095. DOI: 10.3389/fphar.2024. 1321095 .
[22]	LI S F, LI L P, LI J L, et al. miR-203, fine-tunning neuroinflammation by juggling different components of NF-κB signaling[J]. J Neuroinflammation, 2022, 19(1): 84. DOI: 10.1186/s12974-022-02451-9 .
	LI S F, LI L P, LI J L, et al. miR-203, fine-tunning neuroinflammation by juggling different components of NF-κB signaling[J]. J Neuroinflammation, 2022, 19(1): 84. DOI: 10.1186/s12974-022-02451-9 .
[23]	JURČIĆ V, BOLHA L, MATJAŠIČ A, et al. Association between histopathological changes and expression of selected microRNAs in skin of adult patients with IgA vasculitis[J]. Histopathology, 2019, 75(5): 683-693. DOI: 10.1111/his.13927 .
	JURČIĆ V, BOLHA L, MATJAŠIČ A, et al. Association between histopathological changes and expression of selected microRNAs in skin of adult patients with IgA vasculitis[J]. Histopathology, 2019, 75(5): 683-693. DOI: 10.1111/his.13927 .
[24]	CAI Z X, LI K P, YANG K S, et al. Suppression of miR-203-3p inhibits lipopolysaccharide induced human intervertebral disc inflammation and degeneration through upregulating estrogen receptor α[J]. Gene Ther, 2020, 27(9): 417-426. DOI: 10.1038/s41434-019-0118-z .
	CAI Z X, LI K P, YANG K S, et al. Suppression of miR-203-3p inhibits lipopolysaccharide induced human intervertebral disc inflammation and degeneration through upregulating estrogen receptor α[J]. Gene Ther, 2020, 27(9): 417-426. DOI: 10.1038/s41434-019-0118-z .
[25]	ZHANG W, LIU H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells[J]. Cell Res, 2002, 12(1): 9-18. DOI: 10.1038/sj.cr.7290105 .
	ZHANG W, LIU H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells[J]. Cell Res, 2002, 12(1): 9-18. DOI: 10.1038/sj.cr.7290105 .
[26]	HONG H W, LOU S Y, ZHENG F L, et al. Hydnocarpin D attenuates lipopolysaccharide-induced acute lung injury via MAPK/NF-κB and Keap1/Nrf2/HO-1 pathway[J]. Phyto-medicine, 2022, 101: 154143. DOI: 10.1016/j.phymed.2022. 154143 .
	HONG H W, LOU S Y, ZHENG F L, et al. Hydnocarpin D attenuates lipopolysaccharide-induced acute lung injury via MAPK/NF-κB and Keap1/Nrf2/HO-1 pathway[J]. Phyto-medicine, 2022, 101: 154143. DOI: 10.1016/j.phymed.2022. 154143 .
[27]	NGUYEN T T, DENG Z, GUO R Y, et al. Periplaneta americana extract ameliorates LPS-induced acute lung injury via reducing inflammation and oxidative stress[J]. Curr Med Sci, 2023, 43(3): 445-455. DOI: 10.1007/s11596-023-2723-8 .
	NGUYEN T T, DENG Z, GUO R Y, et al. Periplaneta americana extract ameliorates LPS-induced acute lung injury via reducing inflammation and oxidative stress[J]. Curr Med Sci, 2023, 43(3): 445-455. DOI: 10.1007/s11596-023-2723-8 .
[28]	HE X D, SHI J Y, BU L N, et al. Ursodeoxycholic acid alleviates fat embolism syndrome-induced acute lung injury by inhibiting the p38 MAPK/NF-κB signalling pathway through FXR[J]. Biochem Pharmacol, 2024, 230: 116574. DOI: 10.1016/j.bcp.2024.116574 .
	HE X D, SHI J Y, BU L N, et al. Ursodeoxycholic acid alleviates fat embolism syndrome-induced acute lung injury by inhibiting the p38 MAPK/NF-κB signalling pathway through FXR[J]. Biochem Pharmacol, 2024, 230: 116574. DOI: 10.1016/j.bcp.2024.116574 .